Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study
Autor: | Quratul Ann, Henrik Svedsater, Christen Gray, Mark Nixon, Mugdha Gokhale, David Hinds, Mounika Parimi, Naomi J. Boxall |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Budesonide 030213 general clinical medicine Cohort Studies chemistry.chemical_compound 0302 clinical medicine ICS/LABA Budesonide Formoterol Fumarate Drug Combination New user Pharmacology (medical) Anti-Asthmatic Agents Child Original Research Aged 80 and over Beclomethasone General Medicine Middle Aged respiratory system 030220 oncology & carcinogenesis Corticosteroid Female Vilanterol medicine.drug Adult medicine.medical_specialty Adolescent medicine.drug_class Discontinuation Chlorobenzenes Fluticasone propionate Medication Adherence Persistence Young Adult 03 medical and health sciences Internal medicine Administration Inhalation medicine Humans Benzyl Alcohols Aged Retrospective Studies Asthma business.industry Beclometasone dipropionate medicine.disease United Kingdom Androstadienes chemistry Adherence Formoterol business |
Zdroj: | Advances in Therapy |
ISSN: | 1865-8652 0741-238X |
Popis: | Introduction Asthma is associated with significant economic burden. Inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) combination therapies are considered mainstays of treatment. We describe real-world use of ICS/LABAs by comparing treatment persistence and adherence among patients with asthma in the United Kingdom initiating fluticasone furoate/vilanterol (FF/VI) versus budesonide/formoterol (BUD/FM) or beclometasone dipropionate/formoterol (BDP/FM). Methods A retrospective new-user active comparator database study was conducted in the IQVIA Medical Research Database. Propensity score (PS) matching was performed for FF/VI versus BUD/FM, and FF/VI versus BDP/FM. The primary objective was to compare patient treatment persistence (time to discontinuation), while secondary objectives included assessing adherence (mean proportion of days covered [PDC] with medication in the study period) and the proportions of patients achieving ≥ 50% and ≥ 80% PDC. Results New users of FF/VI (N = 966), BUD/FM (N = 5931) and BDP/FM (N = 9607) were identified and PS-matched: FF/VI (n = 945) versus BUD/FM (n = 3272), and FF/VI (n = 902) versus BDP/FM (n = 3465). At 12 months, treatment persistence was 69% (FF/VI), 53% (BUD/FM) and 57% (BDP/FM). The likelihood of treatment discontinuation within 12 months after initiation with FF/VI was 35% lower than with BUD/FM and 31% lower than for BDP/FM (both p |
Databáze: | OpenAIRE |
Externí odkaz: |